Rocket Pharmaceuticals (RCKT) Change in Accured Expenses (2014 - 2026)

Rocket Pharmaceuticals has disclosed Change in Accured Expenses across 13 years of filings, most recently posting -$5.7 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$5.7 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$16.1 million (down 745.55% YoY), and the FY2025 annual result was -$10.4 million, down 12879.01% from the prior year.
• Change in Accured Expenses came in at -$5.7 million for Q1 2026 at Rocket Pharmaceuticals, up from -$10.3 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $6.3 million in Q4 2023 to a low of -$10.3 million in Q4 2025.
• The 5-year median for Change in Accured Expenses is -$491000.0 (2022), against an average of -$1.0 million.
• Peak annual rise in Change in Accured Expenses reached 45214.29% in 2023, while the deepest fall reached 8000.0% in 2023.
• Rocket Pharmaceuticals' Change in Accured Expenses stood at -$14000.0 in 2022, then soared by 45214.29% to $6.3 million in 2023, then slumped by 182.52% to -$5.2 million in 2024, then sank by 97.06% to -$10.3 million in 2025, then jumped by 44.03% to -$5.7 million in 2026.
• The last three Change in Accured Expenses figures came in at -$5.7 million (Q1 2026), -$10.3 million (Q4 2025), and -$80000.0 (Q2 2025), per Business Quant data.